Offered by: Nemours Children's
Locations: Delaware Valley and Pensacola, Fla.
A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients With Recurrent, Refractory, or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
What is the trial about?
To find out what effects low and high doses of lenalidomide have on children, adolescents, and young adults with recurrent/refractory/progressive JPA or OPG.
Who can participate?
Children with juvenile pilocytic astrocytomas (JPA) or an optic pathway glioma (OPG).
What is involved?
Length of study is 24 months. Standard cancer care.